<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72015">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01682642</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000784-25</org_study_id>
    <nct_id>NCT01682642</nct_id>
  </id_info>
  <brief_title>Pregnancy Outcome After IVF/ICSI in Endometriosis Patients Stage I and II</brief_title>
  <official_title>Pregnancy Outcome After IVF/ICSI in Endometriosis Associated Tubal Factor Infertility in Endometriosis Stage I and II. Comparison of Results of IVF After Surgical Therapy Only or After Surgical Vaporisation Associated With Medical Therapy. A Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Jan Palfijn Gent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onze Lieve Vrouw  Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ Jan Palfijn Gent</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study of endometriosis patients we compare a common treatment of surgical therapy
      and medical treatment for 3 months (Zoladex)with patients receiving only surgical therapy.
      In both cases they immediately start IVF treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>2 PN fertilization</measure>
    <time_frame>24 hours after ICSI</time_frame>
    <safety_issue>No</safety_issue>
    <description>laboratory follow up of the fertilized egg during the first 24h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>embryo quality</measure>
    <time_frame>3 to 5 days after egg retrieval</time_frame>
    <safety_issue>No</safety_issue>
    <description>The development of the embryo during the first 3 to 5 days after fertilization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of ongoing pregnancies obtained wich still is the most important issue for the patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Infertility</condition>
  <condition>Endometriosis Stage I and II</condition>
  <arm_group>
    <arm_group_label>Zoladex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vaporization only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoladex</intervention_name>
    <description>after surgical vaporization patients are treated with Zoladex for 3 months</description>
    <arm_group_label>Zoladex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1,2, 3e IVF cycle

          -  endometriosis stage I and II

          -  &lt;38 years old

        Exclusion Criteria:

          -  endometriosis cysts

          -  uterine pathology

          -  endocrinological diseases and problems
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Decleer, gynecologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVF Centrum Jan Palfijn Gent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim Decleer, gynecologist</last_name>
    <phone>0032 9 3259220</phone>
    <email>wim.decleer@janpalfijngent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Devroey, professor</last_name>
    <phone>0032 9 2248070</phone>
    <email>ivf.studie@janpalfijngent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Jan Palfijn</name>
      <address>
        <city>Gent</city>
        <state>Oost-vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim Decleer, gynecologist</last_name>
      <phone>0032 9 2243024</phone>
      <email>wim.decleer@janpalfijngent.be</email>
    </contact>
    <contact_backup>
      <phone>0032 9 2248850</phone>
      <email>ivf.centrum@janpalfijngent.be</email>
    </contact_backup>
    <investigator>
      <last_name>Wim Decleer, gynecologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 7, 2012</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Jan Palfijn Gent</investigator_affiliation>
    <investigator_full_name>Dr. Decleer Wim</investigator_full_name>
    <investigator_title>gynecologist</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>pregnancy</keyword>
  <keyword>IVF/ICSI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
